Hemostemix has drafted the protocol for a Phase I clinical trial to test VesCell™, its autologous stem cell therapy, for longevity and healthspan improvement beyond cardiovascular diseases. The trial aims to assess VesCell™'s effects on quality of life, muscle mass, cognition, immune health, and physical function. Previous studies showed significant improvements in heart function, walking capacity, and quality of life in patients with heart conditions. The company plans regulatory submissions and clinical site activations next, targeting competitions that fund innovations in healthy aging.
Pepeto, a new Ethereum-based cryptocurrency, has launched its page on CoinMarketCap, indicating a Binance listing is near. The project features a working bridge across Ethereum, BNB Chain, and Solana, with zero-cost token transfers and AI contract ch...
Crédit Agricole has signed an agreement to acquire 100% of IKB Deutsche Industriebank, a key financier for Germany's Mittelstand companies. This acquisition strengthens Crédit Agricole's expansion in Germany, Europe's largest economy, aligning with i...
Crédit Agricole has signed an agreement to acquire 100% of IKB Deutsche Industriebank, a key financial partner for Germany's Mittelstand companies. This acquisition aligns with Crédit Agricole's ACT 2028 strategic plan to expand in Europe, particular...
The complicated urinary tract infections (cUTI) market is projected to expand steadily through 2036, driven by increasing antimicrobial resistance, higher rates of recurrent and hospital-acquired infections, and more patients with underlying conditio...
Integrated Power Services (IPS) has acquired Bold Renewables, the exclusive OEM provider of parts and field services for Advanced Energy solar inverters. This acquisition strengthens IPS's renewable energy platform by adding specialized inverter life...
